NSPR · Insider Trading
InspireMD, Inc.
Every open-market purchase and sale reported by NSPR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-23 | Michael Berman | Director | J | — | — |
| 2026-09-23 | Paul Stuka | Director | J | — | — |
| 2026-09-23 | Gary S Roubin | Director | J | — | — |
| 2026-05-29 | Paul Stuka | Director | Buy | +20,000 | +$17.50K |
| 2026-05-21 | Shane Thomas Gleason | Chief Commercial Officer | Sell | −85,295 | −$189.59K |
| 2026-05-15 | Paul Stuka | Director | Buy | +15,000 | +$17.32K |
| 2026-05-13 | Marvin Slosman | CEO and President | Buy | +21,000 | +$25.20K |
| 2026-05-13 | Paul Stuka | Director | Buy | +75,626 | +$88.03K |
| 2026-05-12 | Paul Stuka | Director | Buy | +75,626 | +$88.03K |
| 2026-05-08 | Paul Stuka | Director | Buy | +7,895 | +$9.03K |
| 2026-05-08 | Gary S Roubin | Director | Buy | +90,000 | +$106.20K |
| 2026-05-08 | Scott R. Ward | Director | Buy | +89,250 | +$102.64K |
| 2026-02-23 | Paul Stuka | Director | Buy | +2,710 | +$4.91K |
| 2026-02-02 | Shane Thomas Gleason | Chief Commercial Officer | Sell | −61,194 | −$99.33K |
| 2026-01-16 | Michael A Lawless | Chief Financial Officer | A | +226,695 | — |
| 2026-01-16 | Marvin Slosman | CEO and President | A | +1,114,792 | — |
| 2026-01-16 | Gary S Roubin | Director | A | +88,053 | — |
| 2026-01-16 | Andrea Tommasoli | Chief Operating Officer | A | +226,695 | — |
| 2026-01-16 | Scott R. Ward | Director | A | +88,053 | — |
| 2026-01-16 | Michael Berman | Director | A | +88,053 | — |
| 2026-01-16 | Raymond W Cohen | Director | A | +44,030 | — |
| 2026-01-16 | Danny L. Dearen | Director | A | +44,030 | — |
| 2026-01-16 | Paul Stuka | Director | A | +132,076 | — |
| 2026-01-16 | Shane Thomas Gleason | Chief Commercial Officer | A | +453,390 | — |
| 2025-12-31 | Kathryn Arnold | Director | A | +55,556 | — |
| 2025-12-11 | Paul Stuka | Director | Buy | +5,073 | +$9.18K |
| 2025-12-08 | Paul Stuka | Director | Buy | +5,073 | +$9.44K |
| 2025-12-05 | Paul Stuka | Director | Buy | +10,130 | +$18.74K |
| 2025-11-13 | Paul Stuka | Director | Buy | +13,431 | +$21.76K |
| 2025-10-09 | Gary S Roubin | Director | A | +48,000 | — |
| 2025-09-17 | Thomas J Kester | Director | A | +37,815 | — |
| 2025-08-01 | Gary S Roubin | Director | Buy | +41,322 | +$100.00K |
| 2025-08-01 | Thomas J Kester | Director | Buy | +30,991 | +$75.00K |
| 2025-08-01 | Marvin Slosman | CEO and President | Buy | +10,330 | +$25.00K |
| 2025-08-01 | Paul Stuka | Director | Buy | +20,661 | +$50.00K |
| 2025-07-23 | Gary S Roubin | Director | X | +30,624 | +$42.34K |
| 2025-07-23 | Thomas J Kester | Director | X | +30,624 | +$42.34K |
| 2025-07-23 | Michael Berman | Director | X | +61,248 | +$84.69K |
| 2025-07-23 | Paul Stuka | Director | X | +87,500 | +$120.99K |
| 2025-01-10 | Andrea Tommasoli | Chief Operating Officer | A | +232,616 | — |
| 2025-01-10 | Kathryn Arnold | Director | A | +32,491 | — |
| 2025-01-10 | Craig Shore | CFO and CAO | A | +232,616 | — |
| 2025-01-10 | Marvin Slosman | CEO and President | A | +558,417 | — |
| 2025-01-10 | Michael Berman | Director | A | +32,491 | — |
| 2025-01-10 | Paul Stuka | Director | A | +48,736 | — |
| 2025-01-10 | Shane Thomas Gleason | Chief Commercial Officer | A | +232,616 | — |
| 2025-01-10 | Gary S Roubin | Director | A | +32,491 | — |
| 2025-01-10 | Thomas J Kester | Director | A | +32,491 | — |
| 2025-01-10 | Patrick Verta | EVP Clinical/Medical Affairs | A | +83,072 | — |
| 2025-01-10 | Scott R. Ward | Director | A | +16,245 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Marvin Slosman | CEO and President | 3,556,658 | $1.60M |
| Craig Shore | CFO and CAO | 1,112,460 | $500.61K |
| Shane Thomas Gleason | Chief Commercial Officer | 1,092,119 | $491.45K |
| Paul Stuka | Director | 1,091,575 | $491.21K |
| Andrea Tommasoli | Chief Operating Officer | 954,389 | $429.48K |
| Gary S Roubin | Director | 834,478 | $375.52K |
| Michael A Lawless | Chief Financial Officer | 691,695 | $311.26K |
| Michael Berman | Director | 597,580 | $268.91K |
| Thomas J Kester | Director | 458,573 | $206.36K |
| Patrick Verta | EVP Clinical/Medical Affairs | 311,532 | $140.19K |
| Kathryn Arnold | Director | 303,087 | $136.39K |
| Scott R. Ward | Director | 237,096 | $106.69K |
| Danny L. Dearen | Director | 102,047 | $45.92K |
| Raymond W Cohen | Director | 92,417 | $41.59K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NSPR quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.